Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Paolo Ghia, MD, PhD
Advertisement
Articles by Paolo Ghia, MD, PhD
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Fixed-dose ibrutinib plus venetoclax produces limited second malignancies among patients with chronic lymphocytic leukemia, says Paolo Ghia, MD, PhD.
Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.
Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
PFS With Ibrutinib Combo is ‘Promising’ in Chronic Lymphocytic LeukemiaPublished: December 14th 2023 | Updated:
Ibrutinib Retreatment Yields High Responses in Chronic Lymphocytic LeukemiaPublished: December 21st 2023 | Updated:
Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021Published: June 27th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
4
Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics?
5
